Abstract: The present invention provides anti-aPC antibodies that suppress the inactivation of activated protein C (aPC), and uses thereof. The present inventors screened anti-aPC antibodies, and succeeded in isolating anti-aPC antibodies comprising the activity of suppressing aPC inactivation in blood. The antibodies of the present invention can be used to maintain aPC activity by suppressing aPC inactivation, and can thus be used to sustain aPC bioactivities, such as the activity of suppressing activation of the blood coagulation system, and anti-inflammatory activity. In addition, the present invention provides uses of the antibodies of the present invention in aPC therapy for diseases such as thrombosis and sepsis. The therapeutic effect of aPC can be prolonged in treatment that uses aPC administration by allowing an antibody of the present invention to bind with aPC. The antibodies of the present invention can be used in the treatment and prevention of diseases such as thrombosis and sepsis.

Abstract: The present invention provides anti-PCI antibodies having Protein C inhibitor (PCI)-neutralizing activity, and the uses thereof. Through the generation and screening of anti-PCI antibodies, the inventors successfully isolated anti-PCI antibodies which inhibit PCI's inhibitory effect on the production and activity of activated Protein C (aPC). The antibodies of the present invention suppress PCI's inhibitory effect on aPC production and/or the aPC inactivation by PCI, and thus can be used to maintain aPC activity and sustain the effects of aPC physiological activities, such as suppression of the activation of blood coagulation system and anti-inflammatory functions. The present invention also provides uses of the antibodies of the present invention in treating diseases such as thrombosis and sepsis using aPC. In treatments by aPC administration, the therapeutic effect of aPC can be sustained by administering an antibody of the present invention.

Abstract: The present invention provides anti-aPC antibodies that suppress the inactivation of activated protein C (aPC), and uses thereof. The present inventors screened anti-aPC antibodies, and succeeded in isolating anti-aPC antibodies comprising the activity of suppressing aPC inactivation in blood. The antibodies of the present invention can be used to maintain aPC activity by suppressing aPC inactivation, and can thus be used to sustain aPC bioactivities, such as the activity of suppressing activation of the blood coagulation system, and anti-inflammatory activity. In addition, the present invention provides uses of the antibodies of the present invention in aPC therapy for diseases such as thrombosis and sepsis. The therapeutic effect of aPC can be prolonged in treatment that uses aPC administration by allowing an antibody of the present invention to bind with aPC. The antibodies of the present invention can be used in the treatment and prevention of diseases such as thrombosis and sepsis.

Abstract: A compound of Formula (1): ? wherein R1 represents an amidinophenyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a carbamoylalkyl group, etc.; R4 represents a hydrogen atom, etc.; R5 represents a benzyl group, etc.; R6 represents a hydrogen atom, etc.; and R7 represents an alkylsulfonyl group, etc. A crystal of a complex between factor VIIa/human soluble tissue factor and a low-molecular weight reversible factor VIIa inhibitor. A medium carrying a part or all of structure coordinate data of a complex between human factor VIIa/human soluble tissue factor and a low-molecular weight reversible factor VIIa inhibitor, obtainable by X-ray crystal structure analysis of the crystal. A method for computationally designing a low-molecular weight reversible factor VIIa inhibitor using the coordinate data.

Abstract: A compound of Formula (1): 1

Abstract: Processes for producing a purified conjugated diene comprise feeding a petroleum fraction containing the conjugated diene to an extractive distillation column, feeding an extraction solvent to the extractive distillation column, and extractive-distilling the conjugated diene from the petroleum fraction containing the conjugated diene in the extractive distillation column. The extraction solvent comprises an amide compound, and a heterocyclic aldehyde, aromatic nitro compound or aromatic aldehyde is contained in the extraction solvent within a range of 0.01 to 10 wt. % based on the weight of the extractive solvent. An oxygen concentration in a gas phase of a distillate discharged from the top of the extraction distillation column is controlled to 10 ppm or lower.

Abstract: A process for producing a purified conjugated diene, comprising a step of isolating a conjugated diene from a petroleum fraction containing the conjugated diene by extractive distillation, the step comprising: